Evidence map›Paper›PMID 34206811›Full record

ArticleCancers2021

Protein Aggregation Patterns Inform about Breast Cancer Response to Antiestrogens and Reveal the RNA Ligase RTCB as Mediator of Acquired Tamoxifen Resistance.

Inês Direito, Liliana Monteiro, Tânia Melo, Daniela Figueira, João Lobo, Vera Enes, Gabriela Moura, Rui Henrique, Manuel A S Santos, Carmen Jerónimo and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Insights into the structure and function of the RNA ligase RtcB.Cellular and molecular life sciences : CMLS · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Mitochondria inter-organelle relationships in cancer protein aggregation.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Inês DireitoiBiMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal.
Liliana MonteiroiBiMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0002-8438-0332
Tânia MeloLaQV-REQUIMTE-Associated Laboratory for Green Chemistry of the Network of Chemistry and Technology, University of Aveiro, 3810-193 Aveiro, Portugal.
Daniela FigueiraiBiMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal.
João LoboDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal.ORCID 0000-0001-6829-1391
Vera EnesiBiMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal.
Gabriela MouraiBiMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal.
Rui HenriqueDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal.ORCID 0000-0003-3171-4666
Manuel A S SantosiBiMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal.
Carmen JerónimoDepartment of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal.ORCID 0000-0003-4186-5345
Francisco AmadoLaQV-REQUIMTE-Associated Laboratory for Green Chemistry of the Network of Chemistry and Technology, University of Aveiro, 3810-193 Aveiro, Portugal.
Margarida FardilhaiBiMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0001-7459-9173
Luisa A HelgueroiBiMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0001-8237-2390
University of Aveiro · PTUniversidade do Porto · PTRede de Química e Tecnologia · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein quality control network, including autophagy, the proteasome and the unfolded protein response (UPR), is triggered by stress and is overactive in acquired antiestrogen therapy resistance. We show for the first time that the aggresome load correlates with apoptosis and is increased in antiestrogen-sensitive cells compared to endocrine-resistant variants. LC-MS/MS analysis of the aggregated proteins obtained after 4OH-tamoxifen and Fulvestrant treatment identified proteins with essential function in protein quality control in antiestrogen-sensitive cells, but not in resistant variants. These include the UPR modulators RTCB and PDIA6, as well as many proteasome proteins such as PSMC2 and PSMD11. RTCB is a tRNA and XBP1 ligase and its aggregation induced by antiestrogens correlated with impaired XBP1s expression in sensitive cells. Knock down of RTCB was sufficient to restore sensitivity to tamoxifen in endocrine-resistant cells and increased the formation of aggresomes, leading to apoptotic cell death. Analysis of primary human breast cancer samples and their metastases appearing after endocrine treatment showed that RTCB is only localized to aggresomes in the primary tumors, while total aggresomes, including aggregated RTCB, were significantly reduced in the metastases. Therefore, different protein aggregation patterns may indicate loss of function of essential proteins resulting in enhanced protein aggregation that can be used to identify antiestrogen-resistant breast cancer cells and improve the response to antiestrogenic therapy.

Indexed as

antiestrogen resistancebreast cancerestrogen receptorsprotein aggregationtRNA-splicing ligase RTCB homolog (RTCB)

Identifiers

PMID34206811
PMCPMC8269126
OpenAlexW3176255885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.